"text","label","instanceType","name","uuid:ID","description","id"
"To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","","Objective","OBJ1","a17c8b09-bd54-46ae-8d6f-55d3fa30e829","Main objective","Objective_1"
"To document the safety profile of the xanomeline TTS.","","Objective","OBJ2","60850801-3320-4f49-9124-78e2be2fc93c","Safety","Objective_2"
"To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","","Objective","OBJ3","91a9c738-7b1f-435e-9c24-dcce6908ee65","Behaviour","Objective_3"
"To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","","Objective","OBJ4","5743218f-c6d5-4b1a-bb7b-c54b859c0c44","","Objective_4"
"To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","","Objective","OBJ5","79b78f6e-5149-4999-bef6-554e5749c261","","Objective_5"
"To assess the treatment response as a function of Apo E genotype.","","Objective","OBJ6","8349a952-a2a5-4bbc-9d2a-a78a3992c894","","Objective_6"
